BARD1 Life Sciences Ltd
ASX:BD1

Watchlist Manager
BARD1 Life Sciences Ltd Logo
BARD1 Life Sciences Ltd
ASX:BD1
Watchlist
Price: 1.04 AUD Market Closed
Market Cap: 83.3m AUD

Net Margin
BARD1 Life Sciences Ltd

-2 182.3%
Current
-12 820.7%
Average
1.7%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-2 182.3%
=
Net Income
-11.2m
/
Revenue
511k

Net Margin Across Competitors

No Stocks Found

BARD1 Life Sciences Ltd
Glance View

Market Cap
83.3m AUD
Industry
Health Care

BARD1 Life Sciences Ltd. is a biotechnology company, which engages in the provision of medical services. The firm is engaged in research, development, and commercialization of non-invasive diagnostic products for the early detection of cancer. The Company’s technologies include BARD1, SubB2, NET and hTERT. BARD1 is a biomarker platform covering various tumor markers including nucleic acids, proteins, and autoantibodies for early cancer diagnosis.SubB2M is a pan-cancer probe for monitoring cancer treatment response and recurrence across a wide range of cancers. NET is designed to capture and purify biomarkers, including acids, cells, and exosomes. hTERT is an antibody-based assay to detect hTERT, a component of telomerase, in cells.

BD1 Intrinsic Value
Not Available
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-2 182.3%
=
Net Income
-11.2m
/
Revenue
511k
What is the Net Margin of BARD1 Life Sciences Ltd?

Based on BARD1 Life Sciences Ltd's most recent financial statements, the company has Net Margin of -2 182.3%.

Back to Top